Document 0789
 DOCN  M94B0789
 TI    Increased survival of immunodeficient retrovirus infected mice treated
       with lithium (Meeting abstract).
 DT    9412
 AU    Gallicchio VS; Cibull ML; Hughes NK; Tse KF; Hematology and Oncology
       Division, Department of Internal; Medicine, University of Kentucky
       Medical Center, Lexington, KY; 40536
 SO    Proc Annu Meet Am Assoc Cancer Res; 35:A1824 1994. Unique Identifier :
       AIDSLINE ICDB/94603528
 AB    Murine immunodeficiency virus disease (MAIDS) induced with LP-BM5 MuLV
       shows many similarities to human HIV-infection. The etiological agent is
       a defective MuLV capable of inducing disease with the aid of a helper
       virus. Lithium (Li) influences numerous immunohematopoietic cell types
       and cellular processes that involve cell proliferation and
       differentiation. We report here results of in vivo studies investigating
       the effect of Li in MAIDS. Virus control and Li-treated viral infected
       C57BL6 mice were monitored for survival and development of MAIDS
       pathology. Virus-infected mice were grouped to initiate Li (1 mmol)
       daily as follows: (1) 7-days before virus; (2) 2-days before virus; (3)
       at the same time as virus, and (4) 5-weeks post-virus inoculation. Daily
       Li was continued during the study period. Following 36 wk of
       observation, percent survival was as follows: virus controls, 0%; Li
       7-days 100%; Li 2-days 90%; Li day-0 85%; and Li 5 weeks post-virus 80%.
       Development of lymphoma in Li-treated virus infected mice was reduced
       significantly as measured via ultrastructural, histopathological and
       gross anatomical analysis as measured by thymus involvement,
       lymphadenopathy and splenomegaly (gm): virus control, 1.21 +/- 0.21; Li
       5-weeks post-virus, 0.48 +/- 0.03; Li day 0, 0.28 +/- 0.01; Li 2-days,
       0.25 +/- 0.02; normal control 0.1 +/- 0.01 (P value less than 0.01).
       Myeloid, erythroid and megakaryocyte hematopoietic progenitors were also
       increased compared to virus infected controls. These studies indicate Li
       is an efficacious treatment in modulating MAIDS and raises important
       questions regarding its potential role in the pathophysiological
       processes associated with retroviral infections.
 DE    Animal  Antiviral Agents/ADMINISTRATION & DOSAGE/*THERAPEUTIC USE  Drug
       Administration Schedule  Hematopoietic Stem Cells/DRUG EFFECTS/PATHOLOGY
       Lithium/ADMINISTRATION & DOSAGE/*THERAPEUTIC USE
       Lymphoma/COMPLICATIONS/PREVENTION & CONTROL  Mice  Mice, Inbred C57BL
       Murine Acquired Immunodeficiency Syndrome/COMPLICATIONS/*DRUG
       THERAPY/PATHOLOGY  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).